Windlas Biotech Ltd
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.[1]
- Market Cap ₹ 1,147 Cr.
- Current Price ₹ 552
- High / Low ₹ 591 / 249
- Stock P/E 21.8
- Book Value ₹ 200
- Dividend Yield 0.71 %
- ROCE 14.1 %
- ROE 10.5 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 30.3% CAGR over last 5 years
Cons
- Company has a low return on equity of 12.4% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|
352 | 307 | 329 | 428 | 466 | 513 | 600 | |
313 | 270 | 295 | 373 | 414 | 453 | 528 | |
Operating Profit | 39 | 38 | 34 | 55 | 52 | 60 | 73 |
OPM % | 11% | 12% | 10% | 13% | 11% | 12% | 12% |
4 | 54 | 2 | -19 | 7 | 10 | 11 | |
Interest | 6 | 5 | 3 | 1 | 1 | 1 | 1 |
Depreciation | 17 | 11 | 9 | 13 | 12 | 12 | 13 |
Profit before tax | 20 | 76 | 25 | 22 | 46 | 57 | 70 |
Tax % | 44% | 16% | 34% | 28% | 16% | 25% | |
11 | 64 | 16 | 16 | 38 | 43 | 53 | |
EPS in Rs | 20.04 | 99.55 | 25.28 | 24.69 | 17.48 | 20.04 | 25.19 |
Dividend Payout % | 0% | 0% | 0% | 0% | 20% | 20% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 16% |
TTM: | 21% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 30% |
3 Years: | 37% |
TTM: | 15% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 124% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | 12% |
Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 11 | 10 | 10 |
Reserves | 119 | 187 | 203 | 193 | 384 | 392 | 406 |
57 | 32 | 29 | 32 | 7 | 5 | 6 | |
107 | 73 | 100 | 65 | 90 | 122 | 148 | |
Total Liabilities | 290 | 298 | 338 | 296 | 491 | 529 | 570 |
86 | 64 | 70 | 96 | 91 | 109 | 108 | |
CWIP | 53 | 5 | 0 | 0 | 8 | 15 | 57 |
Investments | 23 | 122 | 116 | 23 | 65 | 107 | 141 |
128 | 107 | 152 | 177 | 327 | 298 | 263 | |
Total Assets | 290 | 298 | 338 | 296 | 491 | 529 | 570 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|
35 | 19 | 25 | 11 | 9 | 61 | |
-11 | -7 | -14 | -20 | -155 | -14 | |
-26 | -6 | -5 | 1 | 130 | -44 | |
Net Cash Flow | -2 | 6 | 5 | -8 | -15 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|
Debtor Days | 69 | 73 | 71 | 68 | 87 | 83 |
Inventory Days | 54 | 36 | 85 | 55 | 71 | 84 |
Days Payable | 130 | 110 | 143 | 53 | 76 | 98 |
Cash Conversion Cycle | -7 | -1 | 13 | 70 | 81 | 69 |
Working Capital Days | -5 | 9 | 26 | 66 | 90 | 73 |
ROCE % | 15% | 12% | 19% | 15% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
19h - Of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR), Regulations, 2015
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 19 Apr
- Compliance Certificate As per Regulation 40 (9) Of The SEBI (LODR) Regulations, 2015 For The Year Ended On March 31, 2024 17 Apr
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
14 Apr - Of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR), Regulations 2015
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Certificate for the Quarter ended March 31, 2024 under Regulation 74(5) of the SEBI DP Regulations, 2018
Annual reports
Concalls
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021Transcript PPT
-
Sep 2021TranscriptNotesPPT
Market Position
Windlas Biotech is amongst the top five players in the domestic pharmaceutical formulations, contract development, and manufacturing organization (CDMO) industry in India, in terms of revenues. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics. [1]